Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
1. Regeneron's therapy shows complete or partial response in all patients with precancerous disorder.
FAQ
Why Very Bullish?
This significant clinical success emphasizes Regeneron's promising pipeline and potential market expansion, reminiscent of previous advancements that drove stock surges.
How important is it?
The article highlights a breakthrough that could directly influence REGN's valuation and investor sentiment moving forward.
Why Long Term?
If approved, this therapy could revolutionize treatment options, likely increasing REGN's market position and revenue streams over time.